UMEM Educational Pearls

Category: Infectious Disease

Title: Daptomycin and MRSA

Posted: 9/15/2009 by Mike Winters, MD (Updated: 10/14/2019)
Click here to contact Mike Winters, MD

 

Daptomycin and MRSA

  • Several new antibiotics are approved for the treatment of infections due to MRSA: linezolid, daptomycin, and tigecycline.
  • Although most are familiar with linezolid, it seems that both daptomycin and tigecycline are being used more frequently.
  • A few pearls on daptomycin:
    • administered IV once daily
    • dose needs to be adjusted in patients with renal failure
    • exerts its effect through a calcium-dependent binding to the bacterial membrane resulting in cell death
  • Importantly, daptomycin is inactivated by pulmonary surfactant and therefore should not be given in patients with suspected MRSA pneumonia.

References

Stryjewski ME, Corey GR. New treatments for methicillin-resistant Staphylococcus aureus. Curr Opin Crit Care 2009;15:403-12.